Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JSP Pharmaceutical Manufacturing (Thailand) PCL's revenue per share for the
three
months ended in Jun. 2026 was ฿0.46.
JSP Pharmaceutical Manufacturing (Thailand) PCL's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was ฿2.00.
Warning Sign:
JSP Pharmaceutical Manufacturing (Thailand) PCL revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of JSP Pharmaceutical Manufacturing (Thailand) PCL was -1.80% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 30.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 15.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
BKK:JSP-R'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.1 Med: 10.2 Max: 30.7
Current: 30.7
During the past 7 years, JSP Pharmaceutical Manufacturing (Thailand) PCL's highest 3-Year average Revenue Per Share Growth Rate was 30.70% per year. The lowest was 3.10% per year. And the median was 10.20% per year.
BKK:JSP-R's 3-Year Revenue Growth Rate is ranked better than 92.36% of 1845
companies
in the Consumer Packaged Goods industry
Industry Median: 3.5
vs BKK:JSP-R: 30.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
JSP Pharmaceutical Manufacturing (Thailand) PCL Revenue per Share Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL Revenue per Share Chart
JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL PS Ratio vs Consumer Packaged Goods Industry
JSP Pharmaceutical Manufacturing (Thailand) PCL Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿2.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Revenue per Share of ฿2.00 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #141 out of 1845 companies in the Consumer Packaged Goods industry, placing it in the top 7.6%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Revenue per Share too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Revenue per Share is ฿2.00. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #141 out of 1845 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Revenue per Share compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #141 out of 1845 companies for Revenue per Share. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the top 8% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Consumer Packaged Goods company?
The median Revenue per Share among Consumer Packaged Goods companies is 3.50, based on 1,845 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median Revenue per Share is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Revenue per Share is ฿2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Revenue per Share is ฿2.00. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Revenue per Share is ฿2.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.
Key valuation signals for BKK:JSP-R:
Revenue per Share: ฿2.00
GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP-R
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP-R has been successfully added to your 
